General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
27-Mar-2018 11:39:34
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%
Announcement Reference
SG180327OTHRO9NI
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
27/03/2018 09:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%

Attachments

Press Release.pdf
Total size =580K